ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure is a major cause of hospitalization, with increasing prevalence in older adults.
• Heart failure with preserved ejection fraction (HFpEF) affects approximately 50% of heart failure patients.
• Historically, HFpEF lacked effective pharmacological treatments for reducing hospitalization and mortality.

Purpose of the Study:

• To provide clinicians with a diagnostic and therapeutic tool for HFpEF.
• To guide clinicians toward optimal diagnostic and treatment pathways for HFpEF patients.
• To highlight the importance of early diagnosis in managing HFpEF.

Main Methods:

• Review of recent clinical trials on gliflozins in HFpEF patients.
• Analysis of diagnostic challenges influenced by comorbidities in HFpEF.
• Guidance on appropriate diagnostic and therapeutic strategies for HFpEF.

Main Results:

• Gliflozins have demonstrated effectiveness in altering the natural history of HFpEF.
• These medications show efficacy in reducing hospitalizations and mortality in HFpEF.
• Early diagnosis is critical for effective treatment initiation.

Conclusions:

• Gliflozins represent a significant advancement in HFpEF treatment.
• Accurate and early diagnosis is essential for improving patient prognosis.
• Clinicians need updated guidance for managing HFpEF, considering comorbidities.